ERAS (Erasca Oncology) Earnings per share growth rate in current year
Erasca, Inc. (ERAS) performance depends on the success of RAS mutation therapies and investment inflows; therefore, a chart of the annual EPS change ratio is available in the GURU.Markets terminal. The value of -121.70 determines the latest valuation metric. The business is not subject to macro cycles, as demand for oncology treatment remains stable and pipeline development relies on attracting leading biochemists through a stock option system.
Analytical breakdowns and data insights for company Erasca, Inc. (ERAS)
- stock price and consensus target price:
- business market valuation indicators:
- balance sheet equity data:
- debt burden and liquidity indicators:
- company profitability and valuation multiples indicators:
ERAS - Net Profit|Company Profit Forecast Erasca, Inc.|ERAS - Price to Earnings Ratio|Price to Future Earnings Ratio Erasca Oncology|ERAS - PEG Multiple|Enterprise Value to EBITDA Ratio Erasca Oncology|ERAS - Operating profit before deduction of amortization|Net earnings per share for the last four quarters Erasca|ERAS - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months erasca.com|ERAS - Earnings per share growth in current year|Expected earnings per share trend next year Erasca, Inc.
Fundamental valuation:ERAS, Erasca Inc
The innovative oncology ecosystem of Erasca, Inc. (ERAS) relies on total patient retention in clinical trials and the influx of R&D capital through licensing agreements. By analyzing the proportional growth of EPS compared to last year, the investor assesses the dynamics of converting revenue into net income per share, which allows for the measurement of cost management efficiency and the business's ability to capitalize on its technological advantage prior to the FDA verdict.
Direct competitors
BeiGene Ltd. - Earnings per share increase in current year|HALO (Halozyme Inc.) - Earnings growth in current year|Earnings per share growth rate in current year Revolution Medicines Corp RVMD|Earnings growth in current year AAPG|CGON - Earnings per share growth rate in current year|Earnings per share growth in current year UroGen Pharma URGN|Earnings per share increase in current year BCAX|Personalis Corp - Earnings growth in current year|DCTH - Earnings growth in current year|Y-mAbs Therapeutics (YMAB) - Earnings per share growth in current year|AURA - Expected net earnings per share growth this year|CADL (Candel Therapeutics Inc.) - Earnings growth in current year|Net earnings per share growth this year Accuray Inc (ARAY)|Earnings growth in current year SLS|Earnings growth in current year Actuate Therapeutics Inc (ACTU)|Citius Oncology, Inc. - Net earnings per share growth this year|Earnings per share increase in current year HURA|Protara Therapeutics, Inc. - Earnings growth in current year|Expected net earnings per share growth this year Fate Therapeutics Inc FATE|aadibio.com (WHWK) - Earnings per share growth in current year|Earnings per share growth this year TCRX|CSBR (Champions Oncology Inc) - Earnings growth in current year|Net earnings per share growth this year XBiotech USA (XBIT)|Net earnings per share growth this year CVM (CEL-SCI Corporation)|Expected net earnings per share growth this year OS Therapies Inc.|Earnings growth in current year RADX (Radiopharm Theranostics)|Artiva Biotherapeutics Inc. (ARTV) - Earnings per share growth rate in current year|ANL - Earnings per share growth in current year|Earnings per share increase in current year VERU (verupharma.com)|TPST: Earnings growth in current year|Xilio Therapeutics (XLO) - Earnings growth in current year|Earnings per share growth in current year Renovaro Biosciences|Mural Bio (MURA) - Expected net earnings per share growth this year|Earnings growth in current year KAPA|Net earnings per share growth this year onkuretherapeutics.com OKUR|Earnings growth in current year GDTC (CytoMed Therapeutics Limited)|Earnings growth in current year Curis Inc. CRIS|APLM - Earnings per share growth in current year|THAR (Tharimmune Corporation) - Earnings per share growth this year|ADVB: Earnings growth in current year|Net earnings per share growth this year genprex.com|CLDI (Calidi Biotherapeutics Inc.) - Earnings growth in current year|Earnings per share growth rate in current year sunshinebiopharma.com SBFM|Earnings per share growth in current year Xenetic Biosciences (XBIO)|SLRX (Salarius Pharma) - Earnings per share increase in current year|Purple Biotech - Net earnings per share growth this year|Earnings per share increase in current year AONC|BeiGene - Earnings growth in current year|Checkpoint Therapeutics Inc. (CKPT) - Net earnings per share growth this year|ELEV (Elevation Oncology) - Net earnings per share growth this year|iCAD (ICAD) - Earnings growth in current year|Earnings per share growth in current year Ikena Oncology Inc.|NTBL: Earnings per share increase in current year|Earnings growth in current year VIRX|MOR - Earnings per share growth rate in current year|Earnings growth in current year NAYA (NAYA Bio)|Ascentage (AAPGV) - Earnings per share growth rate in current year
